tradingkey.logo

Fulgent Genetics Inc

FLGT
查看详细走势图
26.720USD
-0.290-1.07%
收盘 12/26, 16:00美东报价延迟15分钟
824.42M总市值
亏损市盈率 TTM

Fulgent Genetics Inc

26.720
-0.290-1.07%
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

-1.07%

5天

-3.22%

1月

-11.38%

6月

+35.77%

今年开始到现在

+44.67%

1年

+45.45%

查看详细走势图

TradingKey Fulgent Genetics Inc股票评分

单位: USD 更新时间: 2025-12-26

操作建议

Fulgent Genetics Inc当前公司基本面数据相对非常健康,增长潜力很大。当前估值合理,在医疗服务供应商行业排名39/78位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价33.67。中期看,股价处于上升通道。近一个月,市场表现较差,但基本面评分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。

Fulgent Genetics Inc评分

相关信息

行业排名
39 / 78
全市场排名
185 / 4563
所属行业
医疗服务供应商

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

分析师目标

根据 3 位分析师
买入
评级
33.667
目标均价
+20.84%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

Fulgent Genetics Inc亮点

亮点风险
Fulgent Genetics, Inc. is a technology-based company with a laboratory services business and a therapeutic development business. Its laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. Its testing services include comprehensive anatomic pathology testing services, including gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology, and precision diagnostics testing services, including next-generation sequencing (NGS), tests for biopharma research and clinical tests for rare disease, hereditary cancer, reproductive health, and many other diseases.

Fulgent Genetics Inc新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

Fulgent Genetics Inc简介

Fulgent Genetics, Inc. is a technology-based company with a laboratory services business and a therapeutic development business. Its laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. Its testing services include comprehensive anatomic pathology testing services, including gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology, and precision diagnostics testing services, including next-generation sequencing (NGS), tests for biopharma research and clinical tests for rare disease, hereditary cancer, reproductive health, and many other diseases.
公司代码FLGT
公司Fulgent Genetics Inc
CEOHsieh (Ming)
网址https://www.fulgentgenetics.com/

常见问题

Fulgent Genetics Inc(FLGT)的当前股价是多少?

Fulgent Genetics Inc(FLGT)的当前股价是 26.720。

Fulgent Genetics Inc的股票代码是什么?

Fulgent Genetics Inc的股票代码是FLGT。

Fulgent Genetics Inc股票的52周最高点是多少?

Fulgent Genetics Inc股票的52周最高点是31.040。

Fulgent Genetics Inc股票的52周最低点是多少?

Fulgent Genetics Inc股票的52周最低点是14.570。

Fulgent Genetics Inc的市值是多少?

Fulgent Genetics Inc的市值是824.42M。

Fulgent Genetics Inc的净利润是多少?

Fulgent Genetics Inc的净利润为-42.71M。

现在Fulgent Genetics Inc(FLGT)的股票是买入、持有还是卖出?

根据分析师评级,Fulgent Genetics Inc(FLGT)的总体评级为买入,目标价格为33.667。

Fulgent Genetics Inc(FLGT)股票的每股收益(EPS TTM)是多少

Fulgent Genetics Inc(FLGT)股票的每股收益(EPS TTM)是-1.397。
KeyAI